Dr. Kristi Tough DeSapri, MD, owner of Bone & Body Women’s Health, a midlife women’s health medical practice discusses the need for women to understand their risk factors for osteoporosis and find strategies to maintain bone strength and reduce the risk for falls and fractures.
INTERVIEWS
ASCO 2023 – New Data Highlights Three Studies Showing The Impact Of Vitrakvi On Long-Term Efficacy & Safety In Adult And Pediatric Patients
Dr. Svetlana Babajanyan, MD, Executive Medical Director of Medical Affairs for Oncology at Bayer U.S. Pharmaceuticals discusses new findings from three separate studies analyzing the safety & efficacy of Vitrakvi (larotrectinib) in pediatric and adult patients. These data were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
Medicenna – Engineering Superkines to Amplify the Immune System to Combat Challenging Diseases With Unmet Need
Dr. Fahar Merchant, PhD, President and CEO of Medicenna Therapeutics, a clinical-stage immunotherapy company, discusses the company’s Superkine platform and other recent developments.
Dr. Erica P. Gunderson Named 2022-2023 March of Dimes Agnes Higgins Award Winner
Dr. Erica P. Gunderson, PhD, MS, MPH, Senior research scientist at Kaiser Permanente Northern California Division of Research and a professor of Health Systems Science at Kaiser Permanente Bernard J. Tyson School of Medicine discusses being named the recipient of the 2022-2023 March of Dimes Agnes Higgins Award in Maternal-Fetal Nutrition. Her work has produced some of the field’s most important and astounding findings on pregnancy and breastfeeding’s links to diabetes and cardiovascular disease in young women. She received the award at the annual meeting of the Pediatric Academic Society (PAS).
Horizon Presents Data on Investigational Treatment Dazodalibep for Sjögren’s Syndrome
Dr. Ilias Alevizos, DMD, PhD, Executive Medical Director, Clinical Development at Horizon Therapeutics discusses data from the Phase 2 trial results on dazodalibep for two Sjögren’s syndrome populations. This program is the only Sjögren’s Phase 2 trial to meet the primary endpoint in both patient populations.
HKG Epitherapeutics – Pioneering Epigenetics
Professor Moshe Szyf, Founder and CEO of HKG Epitherapeutics, discusses epigenetic research, the company’s novel tools for early detection of cancer and promoting healthy aging, recent data published on the ability of the company’s proprietary epiCervix test to detect cervical cancer in patients sooner and more.
Legacy Healthcare – Botanical Drugs
Saad Harti, founder and CEO of Swiss-based biotech Legacy Healthcare discusses the company’s positive Phase 2/3 data and filing of their lead prescription botanical drug Coacillium for the treatment of an autoimmune condition, alopecia areata. He also talks about a recent survey which found that patients would prefer prescription botanical drugs to treat their chronic diseases.
Scholar Rock – New Data on Investigational Muscle-Targeted SMA Treatment
Dr. Jay Backstrom, MD, MPH, President and CEO, and Ted Myles, COO and CFO of Scholar Rock, a Phase 3 clinical-stage biopharmaceutical company, discusses new TOPAZ 36-month apitegromab extension data reinforcing long-term substantial and sustained improvement of motor function in patients with nonambulatory spinal muscular atrophy (SMA).
Genmab and AbbVie Present New Epcoritamab Data at EHA 2023
Dr. Reid Merryman, MD, an attending physician in the Lymphoma Program at the Dana-Farber Cancer Institute discusses Genmab and AbbVie’s preliminary data from its ongoing phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab in patients across B-Cell lymphomas that were presented at the European Hematology Association’s (EHA) Annual Meeting 2023. Read the abstract here.
Cataract Awareness – Survey Shows Cataract Surgery Can Help Turn Back the Clock for Patients’ Vision
Nationally known ophthalmologist, Dr. Neda Shamie, partner of the Maloney-Shamie Vision Institute in Los Angeles, discusses the signs, symptoms, and treatment options for cataracts, as well as the findings from Alcon’s global “Alcon Eye On Cataract Survey.” Please visit mycataracts.com for more information.